MDMA

A new study is shedding light on how Jewish Americans view psychedelics and their potential for both healing and spiritual connection. As eJewishPhilantropy reported, Jewish Journeys is a national survey designed to understand Jewish perspectives on substances like psilocybin, LSD, MDMA and...

Kendis Gibson, a familiar face in U.S. TV news, is sharing a deeply personal journey in his new book, “Five Trips.” As Variety reported, the memoir offers readers an unflinching look at Gibson's career struggles, mental health battles and his path to healing through psychedelic...

Veterans Affairs (VA) has announced a $1.5 million grant to study MDMA-assisted therapy for veterans with PTSD and alcohol use disorder, marking the first VA-funded psychedelic research in over 50 years. In January 2024, the VA first revealed plans to fund studies on the use of psychedelic...

Kelly Slater, the 11-time World Surf League champion, recently joined the growing conversation around psychedelics. In an appearance on the Everyday Warrior podcast, Slater discussed their transformative potential for mental health and human performance. Widely considered the greatest surfer of...

Georgia lawmakers are exploring the potential of psychedelics in treating veterans' mental health challenges, marking a significant shift in the state's traditionally conservative stance on drug policy. As Medical Xpress reported, a bipartisan panel has recommended allocating up to $5 million to...

A new study published in Scientific Reports revealed that while U.S. healthcare professionals are largely open to the therapeutic potential of psychedelics like psilocybin and MDMA, their understanding of their clinical uses and risks is limited. The research, led by Erin Wang and colleagues from...

Atai Life Sciences (NASDAQ:ATAI), a clinical-stage biopharmaceutical company focused on mental health innovation, announced its third-quarter 2024 financial results Wednesday as well as updates on its clinical and corporate strategies. With notable advancements in its investigational programs, the...

In a recent conversation on The Joe Rogan Experience, Elon Musk and Joe Rogan delivered a sharp critique of the pharmaceutical industry, bashing its history of prioritizing profit over public safety. Their discussion not only touched on well-known scandals like OxyContin and Vioxx but also ventured...

PharmAla Biotech Holdings Inc. (OTC:MDXXF) has announced that it will supply its Good Manufacturing Practice LaNeo MDMA for a clinical trial at Mt. Sinai Health System. The biotechnology company specializes in the research, development, and production of MDMA and novel MDXX-class molecules. "We're...

Imperial College London's Center for Psychedelic Research is recruiting couples who plan to consume MDMA or other psychedelics in real-world settings for a study examining the effects on relationship intimacy, attachment and satisfaction. As DoubleBlind reported, the study will explore both the...

PharmAla Biotech Holdings Inc. (OTC:MDXXF), a Canadian company specializing in MDMA research and development, announced its selection as a supplier for a clinical trial at the University of Texas, San Antonio. The trial will focus on testing a novel dosage form of PharmAla's proprietary LaNeo MDMA...

PharmAla Biotech Holdings Inc. (OTC:MDXXF) announced it has agreed to supply its LaNeo MDMA for a clinical trial at Harvard's Maclean Hospital, a world-leading institution in neuroscience and psychiatric research. This agreement marks a significant step for PharmAla as it continues to expand its...

A new study is shedding light on the complex brain connectivity changes induced by three psychoactive substances: lysergic acid diethylamide (LSD), 3,4-methylenedioxyamphetamine (MDMA) and d-amphetamine. These compounds, while distinct in their classification—psychedelic, entactogen and stimulant,...

The Multidisciplinary Association for Psychedelic Studies (MAPS) is pivoting its focus to state-level initiatives following the U.S. Food and Drug Administration's (FDA) recent denial of MDMA-assisted therapy. As recently reported by Double Blind, MAPS gathered a panel of experts to discuss what...

PharmAla Biotech Holdings Inc. (OTC:MDXXF), a Toronto-based biotechnology company, has secured a contract to supply MDMA for a clinical trial conducted by Johns Hopkins Medicine. This marks a significant milestone for the company as it expands its role in providing MDMA and its novel derivatives...